481 related articles for article (PubMed ID: 18078954)
1. Structural basis for the interaction between focal adhesion kinase and CD4.
Garron ML; Arthos J; Guichou JF; McNally J; Cicala C; Arold ST
J Mol Biol; 2008 Feb; 375(5):1320-8. PubMed ID: 18078954
[TBL] [Abstract][Full Text] [Related]
2. Conformational changes of gp120 in epitopes near the CCR5 binding site are induced by CD4 and a CD4 miniprotein mimetic.
Zhang W; Canziani G; Plugariu C; Wyatt R; Sodroski J; Sweet R; Kwong P; Hendrickson W; Chaiken I
Biochemistry; 1999 Jul; 38(29):9405-16. PubMed ID: 10413516
[TBL] [Abstract][Full Text] [Related]
3. No T-cell tyrosine protein kinase signalling or calcium mobilization after CD4 association with HIV-1 or HIV-1 gp120.
Horak ID; Popovic M; Horak EM; Lucas PJ; Gress RE; June CH; Bolen JB
Nature; 1990 Dec; 348(6301):557-60. PubMed ID: 1701034
[TBL] [Abstract][Full Text] [Related]
4. Mode of action for linear peptide inhibitors of HIV-1 gp120 interactions.
Biorn AC; Cocklin S; Madani N; Si Z; Ivanovic T; Samanen J; Van Ryk DI; Pantophlet R; Burton DR; Freire E; Sodroski J; Chaiken IM
Biochemistry; 2004 Feb; 43(7):1928-38. PubMed ID: 14967033
[TBL] [Abstract][Full Text] [Related]
5. Induction of phosphorylation and intracellular association of CC chemokine receptor 5 and focal adhesion kinase in primary human CD4+ T cells by macrophage-tropic HIV envelope.
Cicala C; Arthos J; Ruiz M; Vaccarezza M; Rubbert A; Riva A; Wildt K; Cohen O; Fauci AS
J Immunol; 1999 Jul; 163(1):420-6. PubMed ID: 10384144
[TBL] [Abstract][Full Text] [Related]
6. Identification of ENV determinants in V3 that influence the molecular anatomy of CCR5 utilization.
Hu Q; Trent JO; Tomaras GD; Wang Z; Murray JL; Conolly SM; Navenot JM; Barry AP; Greenberg ML; Peiper SC
J Mol Biol; 2000 Sep; 302(2):359-75. PubMed ID: 10970739
[TBL] [Abstract][Full Text] [Related]
7. Synthetic CD4 exocyclics inhibit binding of human immunodeficiency virus type 1 envelope to CD4 and virus replication in T lymphocytes.
Zhang X; Gaubin M; Briant L; Srikantan V; Murali R; Saragovi U; Weiner D; Devaux C; Autiero M; Piatier-Tonneau D; Greene MI
Nat Biotechnol; 1997 Feb; 15(2):150-4. PubMed ID: 9035140
[TBL] [Abstract][Full Text] [Related]
8. Regions of the CD4 molecule not involved in virus binding or syncytia formation are required for HIV-1 infection of lymphocytes.
Hasunuma T; Tsubota H; Watanabe M; Chen ZW; Lord CI; Burkly LC; Daley JF; Letvin NL
J Immunol; 1992 Mar; 148(6):1841-6. PubMed ID: 1371792
[TBL] [Abstract][Full Text] [Related]
9. Is the V3 loop involved in HIV binding to CD4?
Dettin M; Ferranti P; Scarinci C; Picariello G; Di Bello C
Biochemistry; 2003 Aug; 42(30):9007-12. PubMed ID: 12885233
[TBL] [Abstract][Full Text] [Related]
10. Force-induced unfolding of the focal adhesion targeting domain and the influence of paxillin binding.
Mofrad MR; Golji J; Abdul Rahim NA; Kamm RD
Mech Chem Biosyst; 2004 Dec; 1(4):253-65. PubMed ID: 16783922
[TBL] [Abstract][Full Text] [Related]
11. Molecular modeling on human CCR5 receptors and complex with CD4 antigens and HIV-1 envelope glycoprotein gp120.
Yang J; Liu CQ
Acta Pharmacol Sin; 2000 Jan; 21(1):29-34. PubMed ID: 11263244
[TBL] [Abstract][Full Text] [Related]
12. SPC3, a V3 loop-derived synthetic peptide inhibitor of HIV-1 infection, binds to cell surface glycosphingolipids.
Delézay O; Hammache D; Fantini J; Yahi N
Biochemistry; 1996 Dec; 35(49):15663-71. PubMed ID: 8961929
[TBL] [Abstract][Full Text] [Related]
13. Molecular analysis of the cytoplasmic domain of CD4: overlapping but noncompetitive requirement for lck association and down-regulation by Nef.
Gratton S; Yao XJ; Venkatesan S; Cohen EA; Sékaly RP
J Immunol; 1996 Oct; 157(8):3305-11. PubMed ID: 8871625
[TBL] [Abstract][Full Text] [Related]
14. Restricted variable residues in the C-terminal segment of HIV-1 V3 loop regulate the molecular anatomy of CCR5 utilization.
Hu Q; Napier KB; Trent JO; Wang Z; Taylor S; Griffin GE; Peiper SC; Shattock RJ
J Mol Biol; 2005 Jul; 350(4):699-712. PubMed ID: 15964018
[TBL] [Abstract][Full Text] [Related]
15. An anti-human immunodeficiency virus multiple antigen peptide encompassing the cleavage region of the env precursor interferes with membrane fusion at a post-CD4 binding step.
Barbouche R; Decroly E; Kieny MP; Fenouillet E
Virology; 2000 Jul; 273(1):169-77. PubMed ID: 10891419
[TBL] [Abstract][Full Text] [Related]
16. NMR studies on the conformation of the CD4 36-59 peptide bound to HIV-1 gp120.
Gizachew D; Moffett DB; Busse SC; Westler WM; Dratz EA; Teintze M
Biochemistry; 1998 Jul; 37(30):10616-25. PubMed ID: 9692951
[TBL] [Abstract][Full Text] [Related]
17. Dynamic reorganization of chemokine receptors, cholesterol, lipid rafts, and adhesion molecules to sites of CD4 engagement.
Nguyen DH; Giri B; Collins G; Taub DD
Exp Cell Res; 2005 Apr; 304(2):559-69. PubMed ID: 15748900
[TBL] [Abstract][Full Text] [Related]
18. Synergistic inhibition of HIV-1 by CD4 binding domain reagents and V3-directed monoclonal antibodies.
Potts BJ; Field KG; Wu Y; Posner M; Cavacini L; White-Scharf M
Virology; 1993 Nov; 197(1):415-9. PubMed ID: 8212576
[TBL] [Abstract][Full Text] [Related]
19. Interaction of an anti-HIV peptide, T22, with gp120 and CD4.
Tamamura H; Otaka A; Murakami T; Ishihara T; Ibuka T; Waki M; Matsumoto A; Yamamoto N; Fujii N
Biochem Biophys Res Commun; 1996 Feb; 219(2):555-9. PubMed ID: 8605026
[TBL] [Abstract][Full Text] [Related]
20. Crystal structure of the broadly cross-reactive HIV-1-neutralizing Fab X5 and fine mapping of its epitope.
Darbha R; Phogat S; Labrijn AF; Shu Y; Gu Y; Andrykovitch M; Zhang MY; Pantophlet R; Martin L; Vita C; Burton DR; Dimitrov DS; Ji X
Biochemistry; 2004 Feb; 43(6):1410-7. PubMed ID: 14769016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
